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Abstract
Despite a comprehensive mapping of the Parkinson's disease (PD)-related mRNA and protein
leucine-rich repeat kinase 2 (LRRK2) in the mammalian brain, its physiological function in healthy
individuals remains enigmatic. Based on its structural features and kinase properties, LRRK2 may
interact with other proteins involved in signalling pathways. Here, we show a widespread LRRK2
mRNA and/or protein expression in expanded or differentiated human mesencephalic neural
progenitor cells (hmNPCs) and in post-mortem substantia nigra PD patients. Using small interfering
RNA duplexes targeting LRRK2 in hmNPCs following their differentiation into glia and neurons, we
observed a reduced number of dopaminergic neurons due to apoptosis in LRRK2 knockdown
samples. LRRK2-deficient hmNPCs exhibited elevated cell cycle- and cell death-related markers. In
conclusion, a reduction of LRRK2 expression in hmNPCs severely impaired dopaminergic
differentiation and/or survival of dopaminergic neurons most likely via preserving or reactivating
the cell cycle.
Background
The pathology of Parkinson's disease (PD) involves the
loss of dopaminergic neurons (DNs) in the substantia
nigra and the presence of intraneuronal accumulations of
aggregated proteins (Lewy bodies) in surviving neurons.
Most PD cases appear to be sporadic. However, several
mutations linked to inherited forms of PD have also been
identified such as parkin, α-synuclein, PINK, DJ-1 [1].
Mutations in the leucine-rich repeat kinase 2 (LRRK2,
PARK8) gene are the most common cause of both auto-
somal-dominant familial and sporadic late-onset cases of
PD identified so far [2].
LRRK2 encodes for dardarin, a large and complex protein
with an approximate molecular weight of 286 kDa that
comprises multiple domains, including leucine-rich
repeat (LRR), ROC-COR GTPase, mitogen-activated pro-
tein kinase kinase kinase (MAPKKK) and WD40 domains
[3,4]. These functional domains support a role in cellular
signalling. The most common mutation, G2019S within
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contributing to LRRK2-mediated pathology through a
toxic gain-of-function mechanism [5]. This gain of func-
tion may contribute to the death of brain cells that pro-
duce dopamine [6,7]. LRRK2 has become a prime
therapeutic target in respect to neuroprotection or symp-
tomatic treatment of PD. Once the pathogenic mecha-
nism of mutated LRRK2 has been identified, we can
search for molecules that are able to repair the signalling
defect in dopamine neurons and prevent them from
dying.
LRRK2 is a ubiquitous protein, which is constitutively
expressed in various brain regions and various cell types
including neurons and glia in the human brain [8,9]. Fur-
ther, it is tightly connected with pathological inclusions in
several neurodegenerative disorders [10]. LRRK2 expres-
sion is high in dopamine-innervated brain areas [8,11].
While LRRK2 mRNA and protein expression were com-
prehensively mapped, the normal physiological role of
LRRK2 protein and its physiological substrates have not
yet been identified.
In this study, we investigated the distribution of LRRK2 in
neural progenitor cells (NPCs) during proliferation and
differentiation. Using RNA interference technology, we
explored the physiological role of LRRK2 protein in NPCs
in respect to cell cycle, dopaminergic differentiation and
survival.
Results
LRRK2 expression in neural progenitors and PD substantia 
nigra
In order to explore LRRK2 protein expression in human
midbrain-derived NPCs (hmNPCs), we selected an anti-
body according to a comprehensive characterization of
various LRRK2 antibodies [12]. LRRK2 protein expression
was examined in several hmNPC preparations that were
cultured for various time periods (passage 4–12). 80–95%
of these proliferating cells that expressed the NPC marker
nestin were also immunoreactive for LRRK2 protein (Fig.
1A–C). Following differentiation, LRRK2 protein was
expressed in both, glial cells (data not shown) and neu-
rons (Fig. 1D–F). In addition, LRRK2 was analyzed in
midbrain sections of 4 patients with a post mortem diagno-
LRRK2 constitutive expression in neural progenitors and terminally differentiated hmNPCsFigure 1
LRRK2 constitutive expression in neural progenitors and terminally differentiated hmNPCs. (A-C) LRRK2 
(green) is co-expressed with nestin (red) in proliferating hmNPC. (D-F) Upon hmNPCs differentiation, LRRK2 was observed in 
dopaminergic neurons (TH-positive). Note the cytoplasmic pattern as previously described. Scale bar: 20 μm (A-C), 75 μm (D-
F).Page 2 of 9
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B). Melanin-positive cells, LRRK2-immunoreactive cells
and cells expressing both melanin and LRRK2 were
counted within the substantia nigra. LRRK2-positive cells
were markedly and significantly reduced (-66%; 202.5 ±
69.0 cells) in PD patients compared to controls (601.8 ±
133.2 cells; Fig. 2E). Accordingly, cells expressing both
melanin and LRRK2 were significantly reduced in patients
(-73%; 148.8 ± 64.1 cells) compared to controls (536.3 ±
130.5 cells; Fig. 2E).
LRRK2 down-regulation leads to a reduction of TH 
expression
Semi-quantitative RT-PCR analysis (relative to HMBS
expression as a house keeping gene) of siLRRK2 vs. scram-
bled (non-silencing control) siRNA samples revealed a
reduction in LRRK2 mRNA by 54.9 ± 30.1% following
nucleofection and 72 h expansion using standard condi-
tions. By contrast, the mRNA level of the NPC marker nes-
tin did not exhibit a significant difference compared to
scrambled control samples (95.3 ± 37%). RT-PCR data
were confirmed using immunoblotting and densiometric
quantification of bands demonstrating a significant
LRRK2 protein knockdown (43 ± 11% of control; P =
0.003, t-test) and a non-significant nestin down-regula-
tion (80 ± 1%; Fig. 3A) in expanding hmNPCs, 72 h post-
nucleofection. The knockdown of LRRK2 in hmNPCs fol-
lowing 2 weeks of differentiation did not significantly
affect neuronal (Tuj1) or glial (GFAP) differentiation, but
resulted in a reduced capacity to differentiate into
dopaminergic neurons (40 ± 17% of control scrambled
siRNA; Fig. 3C, D). The number of TH-immunoreactive
(TH-IR) cells per field in LRRK2 siRNA transfected was
reduced to 55.0 ± 2.6 vs. 116.7 ± 4.6 cells counted in
scrambled control samples (Fig. 3E).
LRRK2 deficient dopaminergic neurons die presumably by 
apoptosis
To assess the potential loss of dopaminergic neurons by
apoptosis scrambled and siRNA treated hmNPCs cultures
were stained for cleaved caspase-3 and TH (double immu-
nocytochemistry). Caspase-3 is considered to execute
apoptotic cell death in many cell types including
dopaminergic neurons when activated via cleavage
[13,14]. Cells transfected with scrambled control RNA did
not show activated caspase-3 expression. By contrast,
siLRRK2 expressing differentiated hmNPCs exhibited
overt cell death (Figure 4A). On closer inspection, cleaved
caspase-3-positive cells revealed TH/caspase-3 co-expres-
sion indicating a loss of dopaminergic cells via apoptosis
(Fig. 4B). Counting of TH/caspase-3 double-positive cells
has revealed 17.7 ± 0.9 TH+ cells with activated caspase-3
per visual field (Fig. 3E).
Cell cycle preservation or reactivation in LRRK2 deficient 
hmNPCS
To further explore underlying reasons for cell death fol-
lowing LRRK2 protein down-regulation, signal transduc-
tion proteins from the MAPK, Akt/PKB and GSK signalling
cascades were studied by antibody microarray analysis. In
addition, cell cycle regulation, apoptosis and transcrip-
tion factors were analyzed using the same method.
Microphotograph of substantia nigra from controls or PD patients stained for LRRK2Figure 2
Microphotograph of substantia nigra from controls or PD patients stained for LRRK2. (A, B) control coronal mid-
brain paraffin section (5 μm) and (C, D) PD midbrain section in 200× (scale bar 50 μm) or 800× (scale bar 20 μm) magnifica-
tion displaying the substantial loss of cells expressing melanin and LRRK2. The arrows exemplarily show cells expressing both 
LRRK2 and melanin. (E) Cell counts of melanin and LRRK2 expressing cells in substantia nigra of controls and patients with Par-
kinson's disease. Note the significant loss of cells expressing melanin and LRRK2 (** P < 0.01, unpaired Student's t-test).Page 3 of 9
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increased concentrations of cyclin A, cyclin B1, cyclin D1,
p18 and increased phosphorylation of apoptosis protein
p53 (at Ser15) but non of CDKs was observed in hmNPCs
expressing siLRRK2 versus scrambled siRNA (Figure 5). To
ensure that the observed differences were due to the
knockdown of LRRK2, we also calculated the variability
between samples transfected with scrambled RNA which
were less than 10 arbitrary units (a. u.) and were negligible
(data not shown). The up-regulation of cyclin A, cyclin D1
and the early mitotic marker cyclin B1 suggests cell cycle
reactivation provoked by LRRK2 down-regulation. Activa-
tion of p53 can lead to either cell cycle arrest and DNA
repair or apoptosis [15]. Phosphorylation of p53 at Ser15
is usually induced by DNA damage and leads to a reduced
interaction between p53 and its negative regulator, the
oncoprotein MDM2 [16]. MDM2 inhibits p53 accumula-
tion by targeting it for ubiquitination and proteasomal
degradation [17]. Phosphorylation thus impairs the abil-
ity of MDM2 to bind p53, promoting both the accumula-
tion and activation of p53 [18]. A PCR array analysis of 96
cell-cycle regulators revealed indeed increased (cyclin D1
[CCND1], cyclin-dependent kinase inhibitor 1A
[CDKN1A] and replication protein A3 [RPA3]) or reduced
(cyclin B2 [CCNB2] and cyclin-dependant kinase 1
[CDK1/CDC 2]) expression of five fundamental cell-cycle
regulators (Fig. 6A). Cyclin D1 promotes cell-cycle pro-
gression and its overexpression is known to correlate with
the early onset of cancer and risk of tumor progression
and metastasis [19]. RPA3 is important for DNA synthesis
and repair [20]. CDKN1A (p21/CIF1) is activated upon
DNA-damage by the p53 pathway [21] strengthening the
antibody microarray results. The complex of cyclin B/cdc-
2 was originally defined as M phase-promoting factor,
capable of inducing M phase in immature G2 oocytes
[22], but cyclin B mRNA is also known to become instable
after DNA damage [23]. In the same cultures, we recog-
nized the proliferation marker Ki67 co-expressed in dying
dopaminergic neurons (Fig. 6C). In parallel control cul-
tures (scrambled siRNA), Ki67 was absent in TH-immu-
noreactive cells but present in other, presumably glial,
cells (Fig. 6B).
Discussion
In the present study we investigated a possible role of
non-mutated LRRK2 for the differentiation and/or sur-
vival of human dopaminergic neurons. Widespread
LRRK2 involvement in dopaminergic differentiation of hmN-PCsFigure 3
LRRK2 involvement in dopaminergic differentiation 
of hmNPCs. (A) Representative samples of expanded hmN-
PCs quantified for LRRK2 or nestin mRNA level as deter-
mined 72 h upon nucleofection with either non-specific 
siRNA (scrambled control siRNA) or LRRK2-specific siRNA, 
both relative to HMBS mRNA expression. (B) Immunoblot 
demonstrating knockdown of LRRK2 protein expression in 
hmNPCs, observed 72 h after siRNA delivery. (C) Densito-
metric analysis of Western blots exhibiting relative band 
intensities of unaffected neuronal (Tuj1) and glial (GFAP) 
markers but reduced TH expression, all normalized to con-
trol samples. β-actin served as loading control (D). Quantifi-
cation of TH+ and TH/caspase-3 double-positive cells 
expressed as number of immunoreactive cells per visual field 
(n = 6). Data are means of 3 independent experiments ± 
S.E.M. *P < 0.05 vs. scrambled siRNA sample.
LRRK2 down-regulation in differentiated neuralprogenitors induces cell deathFig re 4
LRRK2 down-regulation in differentiated neuralpro-
genitors induces cell death. (A) Partial LRRK2 protein 
reduction induced appearance of dying cells as detected by 
immunostaining against cleaved caspase-3. Note plenty of red 
cells expressing activated caspase-3 at lower magnification (A 
– right panel). Caspase-3 containing cells were not observed 
in hmNPCs treated with scrambled siRNA before differentia-
tion (A – left panel). (B) Some of the TH+ cells in siLRRK2 
cultures were also positive for acivated caspase-3 (higher 
magnification).Page 4 of 9
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suggests an important physiological role that has not been
identified to date [24]. Consistent with the quite strong
LRRK2 expression in the murine subventricular zone [25],
a region of in vivo neurogenesis in the adult brain, we
found high nestin/LRRK2 co-expression in expanded
human mesencephalic neural progenitor cells (hmNPCs)
in vitro. This characteristic of hmNPCs allowed us to
knockdown the LRRK2 protein expression in progenitor
cells using silencing RNA technology and to track their
course of differentiation afterwards. siLRRK2 nucleofected
hmNPCs produced less dopaminergic neurons when
compared to scrambled controls possibly as a conse-
quence of cell death driven by activated caspase-3 within
DNs. Based on results obtained with comprehensive PCR
array and antibody microarray analysis, we further postu-
late that the observed cell death results from cell cycle
preservation or even reactivation in DNs. Most of the 44
examined proteins that were up-regulated in LRRK2 defi-
cient differentiated hmNPCs belong to cell cycle-related
proteins. Increased overall serine and tyrosine phosphor-
ylation was also detected. Cell-cycle PCR array analysis
likewise revealed regulation of five fundamental cell-cycle
regulators. Together with the activation of other cell-cycle
regulators, the down-regulation of cyclin B/cdc-2 by the
LRRK2 knockdown suggests an activation of the cell cycle
without the ability to progress through M-phase, an acti-
vation that might report DNA damage and might lead to
apoptosis. Gene array experiments in neuroblastoma cells
also revealed that knock-down of LRRK2 affects, among
others, cell cycle genes and p53 signalling cascades [26].
Components of Wnt/β-catenin signalling pathway were
also dysregulated along with 14 genes belonging to "nerv-
ous system development" category, highlighting the
importance of LRRK2 for the whole brain and dopamin-
ergic system development. Upregulation of p53 protein,
plays a role in the degeneration of the nigro-striatal
dopaminergic neurons in the parkinsonian brain [27].
Phosphorylation of p53, also detected in LRRK2 deficient
hmNPCs, might influence cell death in dopaminergic
neurons [28].
Cell cycle reactivation and cell death induction in LRRK2 deficient hmNPCsFigure 5
Cell cycle reactivation and cell death induction in 
LRRK2 deficient hmNPCs. Human mesencephalic neuro-
progenitors were nucleofected with corresponding siRNAs 
(scrambled or LRRK2 siRNA) and differentiated for 2 weeks 
after a 24 h recovery period. Protein extracts were sub-
jected to antibody microarray (Signal.screen 44 F employing 
44 antibodies belonging to signalling cascades: MAPK, Akt/
PKB, GSK, cell cycle regulation, apoptosis and transcription 
factors). Here we illustrate the comparison of sample 7 
(LRRK2 siRNA) vs. sample 8 (scrambled siRNA): (A) the 
original spot intensities, (B) the differences and (C) selected 
averages presented in arbitrary units (a. u.). The differences 
in the intensities lower 10 a.u. should be neglected since they 
lay outside the test reliability.
LRRK2 deficient postmitotic DNs express proliferation markerFigure 6
LRRK2 deficient postmitotic DNs express prolifera-
tion marker. LRRK2 siRNA-treated (white bars) or control 
(black bars) hmNPC RNA displayed activation or reduction 
of important cell-cycle regulators in differentiated cells (A). 
LRRK2 siRNA-treated or control (scrambled siRNA) hmN-
PCs were co-stained for TH and Ki67 (B, C). Note a reduc-
tion in LRRK2 expression and disappearance of protrusions 
that normally characterize healthy dopaminergic cells (C). 
Terminally differentiated TH+ hmNPCs never exhibited Ki67 
proliferation marker (B) which appeared in dopaminergic 
(TH+) siLRRK2 treated samples (arrows in C), particularly 
visible at higher magnification (insert corresponds to aster-
isk).Page 5 of 9
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erate, yet the expression of cell cycle markers, cyclins or
cyclin dependent kinases (CDKs) in the postnatal or adult
brain is still a matter of controversial debate [29,30]. Ter-
minal differentiation is considered to be an irreversible
state and neurons do not spontaneously re-enter the cell
cycle, but they can be forced to do so. Studies in cell-cul-
ture systems and in post-mortem tissue from diseased
human brain suggested a link between cell-cycle reactiva-
tion and neurodegeneration [31,32]. Pathologic DNs
aberrantly expressed proliferating cell nuclear antigen
(PCNA) and the transcription factor E2F-1, both in vitro
and in vivo, following 1-methyl-4-phenylpyridinium
(MPP+) intoxication, as well as in PD patients [33]. There
is thus direct evidence of DNA replication preceding cell
death in neurodegenerative diseases [34]. Another study
on mutant tau-induced neurodegeneration in Drosophila
indicated a role for cell-cycle activation downstream of
tau phosphorylation subsequently leading to apoptosis
[35]. Here, we demonstrate both, a total serine and tyro-
sine phosphorylation and cell death in DNs developed
from LRRK2 deficient neuroprogenitors in vitro. In paral-
lel, we recognized the proliferation marker Ki67 co-
expressed in dying DNs that was not detected in control
cells. Substantia nigra of PD patients showed a reduction of
the number of LRRK2-immunoreactive cells when com-
pared to healthy midbrain samples. The same is true for
melanin containing cells, most of which are dopaminergic
neurons. Both, LRRK2+ and LRRK2/melanin double-pos-
itive neurons are similar and significantly less in SN of PD
patients in comparison to healthy SN, probably due to a
common reduction of DA neurons in PD. This finding
supports our hypothesis of LRKK2 expression in DA neu-
rons. We did not perform double labelling in post-mortem
human tissue (e.g. for TH to identify dopaminergic neu-
rons) due to technical issues. Instead, we used melanin as
a marker for dopaminergic neurons, although being
aware that some phagocytosing cells may also contain
melanin, which account for the modest reduction of mel-
anin-containing cells in PD patients. On the other hand,
the prominent reduction of LRRK2-immunoreactive cells,
which was observed previously [9], compared to melanin
containing cells may also indicate that down-regulation of
LRKK2 precedes DNs death. This hypothesis is in line with
our in vitro data showing siRNA knockdown of LRRK2 in
human midbrain neural progenitors prior to differentia-
tion, which also induced loss of DNs, most likely via acti-
vation of cell cycle genes and subsequent apoptosis. The
generation of dopaminergic neurons in the adult brain is
still a matter of discussion [36-38], which at present does
not convincingly support adult dopaminergic neurogene-
sis [39]. Thus, if our findings of cell cycle activation and
loss of dopaminergic neurons were of relevance to Parkin-
son's disease, a concept of cell cycle reactivation impairing
survival mechanisms of dopaminergic neurons would be
appropriate. However, our current experiments show
merely that reducing the expression of LRRK2 in develop-
ing dopaminergic neurons reduces their number and
induces apoptosis in remaining dopaminergic neurons
associated with an activation of cell cycle genes.
It is still disputed whether mutations in the LRRK2 gene
that account for familial PD reduce or increase the func-
tional (especially kinase) activity of this protein. Some
studies suggest that mutant LRRK2 induces a gain-of-func-
tion [6,40]. On the other hand, mutant LRRK2 also failed
to promote protective effects conferred by the wild-type
protein [41]. The latter findings are in agreement with our
present data indicating that a lack of LRRK2 is critical dur-
ing differentiation towards dopaminergic neurons. How-
ever, both findings do not preclude that there is a gain of
kinase activity induced by the mutations.
Taken together, we hypothesize that insufficient LRRK2
might harm the differentiation and/or survival of
dopaminergic neurons. LRRK2 seems to be involved in
cell cycle regulation. Whether it directly inhibits cells cycle
genes or acts indirectly via activators or suppressors of the
cell cycle can not be answered based on our data. Future
studies shall reveal which part of the complex cell cycle
machinery is altered via LRRK2.
Materials and methods
Isolation, characterization and propagation of human 
NPCs (hNPCs)
Human fetal midbrain tissue was used to generate human
midbrain NPCs cultures (hmNPCs). Samples were har-
vested and supplied by Advanced Bioscience Resources
Inc., Alameda, CA, according to NIH and local IRB guide-
lines. Prior to experimental procedures primary cells from
the ventral mesencephalon were characterized by FACS,
immunocytochemistry and RT-PCR for markers of early
and late DA differentiation as described. Cells were
expanded for prolonged periods (> 10 passages) in
reduced atmospheric oxygen (3%) [42,43].
Differentiation of hmNPCs
Differentiation of hmNPCs was induced via replacement
of expansion media by defined media without mitogens
but with 2% B-27 (Invitrogen), 5 μM forskoline (Sigma-
Aldrich Chemie GmbH Munich, Germany) and 100 pg/
ml IL-1β (Sigma). Prior to immunostaining or protein
extraction, hmNPCs were allowed to differentiate for 2
weeks.
RNA interference treatment
We tested several different double-stranded siRNAs aimed
to reduce expression levels of LRRK2 protein. The best
effects were obtained with a target-specific LRRK2 siRNA
and control siRNA-A (scrambled sequence siRNA) thatPage 6 of 9
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ogy, Inc., Santa Cruz, CA, USA). Both siRNAs were recon-
stituted under RNase-free conditions using the supplied
buffers according to the protocol of the manufacturer.
Delivery of siRNA into NPCs was performed with the
Nucleofector technology using the mouse Nucleofector
kit (Amaxa Biosystems, Koeln, Germany). Transfection
efficiency was checked via transfecting the cells with Cy3-
conjugated negative control siRNA duplex (QIAGEN,
Hilden, Germany). hmNPCs were nucleofected either
with LRRK2 siRNA or scrambled siRNA at the concentra-
tion of 100 pmol siRNA per 1 × 106 cells following by fur-
ther 72 h expansion [44]. Alternatively, nucleofected cells
were the next day initiated to differentiate for 2 weeks.
Semiquantitative real-time RT-PCR analysis
Total cellular RNA was extracted from siRNA nucleofected
NPCs using RNAeasy total RNA purification kit followed
by treatment with RNase-free DNase (Qiagen, Hilden,
Germany). Semi-quantitative real-time one step RT-PCR
was carried out using the Stratagene system (MX3000P™
Stratagene, Heidelberg, Germany), and amplification was
monitored and analyzed by measuring the binding of flu-
orescent SYBR Green I to double-stranded DNA. 1 μl (50
ng) of total RNA was reverse-transcribed and subse-
quently amplified using QuantiTect SYBR Green RT-PCR
Master mix (Qiagen) and 0.5 μmol/l of both sense and
antisense primers. The sequences for forward and reverse
primers used for the target gene (TG) human LRRK2 were
as follows: 5'-CTT GGC TTG GTC CTT TAT TTCC-3' and
5'-CCT GAG GCT GTT CCT TCT TCC-3'. The primers for
the reference gene (RG) HMBS (hydroxymethylbilane
synthase) were as follows: 5'-TCG GGG AAA CCT CAA
CAC C-3' and 5'-CCT GGC CCA CAG CAT ACA T-3'. The
efficiency of product formation by PCR was estimated
from plots of Ct values versus serial dilutions, measured
three times with different RNA samples. The relative RNA
content was determined using the formula of the compar-
ative cycle threshold (Ct): TG/RG = 2Ct(RG)-Ct(TG) [45].
PCR Superarray
Total RNA was extracted from siRNA nucleofected differ-
entiated hmNPCs using RNAeasy total RNA purification
kit followed by treatment with RNase-free DNase (Qia-
gen, Hilden, Germany). The pathway-focused (cell-cycle)
RT2 Profiler™ PCR Array System (SABiosciences, Freder-
ick, USA) was employed according to the manufacturer's
manual. In short, cDNA was prepared, mixed with RT2
qPCR Master Mix and aliquoted across the 96-well PCR
array. Thermal cycling was done and collected data were
subsequently analyzed using the provided analysis
spreadsheet.
Immunofluorescence
hmNPCs were grown on sterile glass cover slips, fixed with
4% paraformaldehyde in PBS for 10 min at room temper-
ature and washed with PBS, counterstained with the DNA-
binding dye 4'-6-Diamidino-2-phenylindole (DAPI, 2 μg/
ml in PBS) followed by incubation in blocking buffer. The
following primary antibodies were used: mouse mono-
clonal anti-nestin (Pharmingen, San Diego, CA, USA),
rabbit polyclonal anti-β-tubulin III (anti-Tuj1; Covance,
Freiburg, Germany), rabbit polyclonal anti-tyrosine
hydroxylase (Santa Cruz Biotechnology, Inc., Santa Cruz,
CA, USA), sheep polyclonal anti-tyrosine hydroxylase
(Pel-Freez, Rogers, AK), rabbit polyclonal anti-Ki67 anti-
gen (Novocastra Laboratories Ltd, Newcastle upon Tyne,
UK); rabbit polyclonal anti-LRRK2 (NB300-267; Novus
Biologicals, Littleton, CO, USA); rabbit polyclonal
cleaved caspase-3 (Cell Signalling Technology, Inc., Dan-
vers, USA). Finally, fluorescent secondary antibodies,
Alexa Fluor® 488 conjugate or Alexa Fluor® 594 conjugate
(Molecular Probes, Eugene, USA) were used. Coverslips
were mounted onto glass slides and examined by a confo-
cal laser scanning microscope (LSM 510, Zeiss, Oberko-
chen, Germany) at an excitation wavelength of 594 nm
(helium/neon, red Alexa 594-immunofluorescence), and
488 nm (argon, yellow-green Alexa 488-immunofluores-
cence). Alternatively, glass slides were examined under a
fluorescence microscope (Zeiss Axiovert 200). Acquisition
of the immunostained cells was performed using the
Image-analysis software AxioVision 4 (Carl Zeiss AG, Jena,
Germany).
Immunohistotochemistry
Two paraffin sections (5 – 6 μM; n = 2) of the midbrain
were made from 4 patients with neuropathologic diagno-
sis of idiopathic PD and 4 controls, (mean age 64 ± 22
years), respectively. Sections were deparaffinized in Xylol
for 3 × 10 min and hydrated in descending alcohol con-
centrations. After a microwave treatment with 10% citrate
buffer (DAKO, Code # S2031) at 600 W 4 × 4 min and
consecutive washing in PBS, sections were blocked in dry
milk (5 g/l). Peroxidase blocking preceded overnight
incubation in LRRK2 primary antibody (1:200, NB300-
267; Novus Biologicals, Littleton, CO, USA). Incubation
in biotinylated secondary antibody Link DAKO LSAB 2
System (k0675, Dako, Hamburg, Germany) followed by
additional washing steps. Streptavidine-HRP DAKO LSAB
2 system was used for the Streptavidine conjugation.
DAKO DAB (k3468, Dako, Hamburg, Germany) was used
as substrate chromogen. Counterstaining was performed
using Haemalaun (Mayer). Sections were dehydrated in
ascending alcohol concentrations and Xylol and mounted
in Entellan medium.
Western blot analysis
Approximately 5 × 106 hmNPCs were harvested and lysed
in 0.5 ml lysis buffer containing 10 mM HEPES-KOH (pH
7.9), 10 mM KCl, 1.5 mM MgCl2, 0.1% NP-40 and pro-
tease inhibitor cocktail (Roche). Running and blotting of
proteins, membrane blocking and incubation with anti-Page 7 of 9
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as reported [46]. Primary antibodies used for immunob-
lotting were as follows: mouse monoclonal anti-Nestin
(Pharmingen); mouse monoclonal anti-GFAP (Chemicon
International, Hampshire, UK); rabbit polyclonal anti-β-
tubulin III (Covance); rabbit polyclonal anti-TH (Santa
Cruz); rabbit polyclonal anti-LRRK2 (Novus); mouse
monoclonal anti-actin (MP Biomedicals, Eschwege, Ger-
many).
Antibody microarray
The microarray analysis was performed using antibody
microarrays Signal.screen 44 F from the BIOSCORA
GmbH (Leipzig, Germany). The microarray contains anti-
bodies for detection of signal transduction proteins from
the following signalling cascades: MAPK, Akt/PKB, GSK,
cell cycle regulation, apoptosis and transcription factors
(14 subarrays, 44 antibodies each, as well as 3 calibrator
proteins/slide, totally 756 detection points/slide). Debris-
free cell lysates (scrambled samples and siLRRK2 samples)
were applied separately onto identical antibody subarrays
printed on modified surface of the standard microscope
glass slide. Protein concentration was 0,9 mg/ml for each
sample. Protein binding and detection were performed
according to experimental protocol of the manufacture.
Read-out of signal intensities of the bound proteins (spot
intensities) was performed using the Cy-3 (green) channel
of the VersArray Microarray Scanner (Bio Rad). Signal
intensities of the separate subarrays were measured using
Quanti.screen microarray analysis software (BIOSCORA
GmbH, Leipzig).
Statistical analysis
Normally distributed data were subjected to statistical
analyses as appropriate (t-test or ANOVA) using the Sigm-
aStat software package (Jandel Corp., San Rafael, CA).
Results are expressed as the mean ± S.E.M. Statistical sig-
nificance was accepted at P < 0.05.
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MAPK: mitogen-activated protein kinase; MAPKKK:
mitogen-activated protein kinase kinase kinase; MPP+: 1-
methyl-4-phenylpyridinium; PD: Parkinson's disease;
siRNA: small interfering ribonucleic acid; TH: tyrosine
hydroxylase; Tuj1: Neuronal class III β-tubulin.
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